UK-based NodThera Ltd has raised £28 million in Series A financing to develop small molecule drugs to treat diseases driven by chronic inflammation. The financing was co-led by Sofinnova Partners and 5AM Ventures with further participation by Epidarex Capital and F-Prime Capital Partners.
